BR112012022896A2 - vacinas adjuvantes para meningococos do sorogrupo b - Google Patents
vacinas adjuvantes para meningococos do sorogrupo bInfo
- Publication number
- BR112012022896A2 BR112012022896A2 BR112012022896A BR112012022896A BR112012022896A2 BR 112012022896 A2 BR112012022896 A2 BR 112012022896A2 BR 112012022896 A BR112012022896 A BR 112012022896A BR 112012022896 A BR112012022896 A BR 112012022896A BR 112012022896 A2 BR112012022896 A2 BR 112012022896A2
- Authority
- BR
- Brazil
- Prior art keywords
- serogroup
- meningococci
- adjuvant vaccines
- oligonucleotide
- vaccines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
vacinas adjuvantes para meningococos do sorogrupo b. uma composição imunológica compreende (i) um oligonucleotídeo estimulador e um polímero policatiônico, em que o oligonucleotídeo e o polímero preferivelmente se associam um ao outro para formar um complexo e (ii) um antígeno meningócio do sorogrupo b. na maioria das modalidades, a composição não inclui um sal de alumínio e não inclui uma emulsão de óleo em água.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31533610P | 2010-03-18 | 2010-03-18 | |
US31757210P | 2010-03-25 | 2010-03-25 | |
PCT/IB2011/051148 WO2012020326A1 (en) | 2010-03-18 | 2011-03-18 | Adjuvanted vaccines for serogroup b meningococcus |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012022896A2 true BR112012022896A2 (pt) | 2018-03-27 |
Family
ID=44512325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022896A BR112012022896A2 (pt) | 2010-03-18 | 2011-03-18 | vacinas adjuvantes para meningococos do sorogrupo b |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130071422A1 (pt) |
EP (1) | EP2547357A1 (pt) |
JP (1) | JP2013522287A (pt) |
CN (1) | CN102802662A (pt) |
AU (1) | AU2011288203A1 (pt) |
BR (1) | BR112012022896A2 (pt) |
CA (1) | CA2793510A1 (pt) |
MX (1) | MX2012010609A (pt) |
WO (1) | WO2012020326A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
WO2012025873A2 (en) | 2010-08-23 | 2012-03-01 | Wyeth Llc | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
US9283270B2 (en) * | 2012-01-20 | 2016-03-15 | Serum Institute Of India Ltd. | Method for stabilization of biological molecules |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
SG10201602558UA (en) | 2012-03-09 | 2016-05-30 | Pfizer | Neisseria meningitidis compositions and methods thereof |
CA2882619A1 (en) * | 2012-09-06 | 2014-03-13 | Novartis Ag | Combination vaccines with serogroup b meningococcus and d/t/p |
EP3400960A1 (en) * | 2012-09-18 | 2018-11-14 | GlaxoSmithKline Biologicals S.A. | Outer membrane vesicles |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
US10138594B2 (en) * | 2014-09-26 | 2018-11-27 | The Chemours Company Fc, Llc | Partially fluorinated urethane based coatings |
BR112017017460A2 (pt) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | composições de neisseria meningitidis e métodos das mesmas |
CN104707134A (zh) * | 2015-03-27 | 2015-06-17 | 成都欧林生物科技股份有限公司 | 一种无细胞百日破联合疫苗及其制备方法 |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
PL240667B1 (pl) * | 2018-03-26 | 2022-05-16 | Gdanski Univ Medyczny | Peptyd, będący fragmentem płytkopochodnego czynnika wzrostu do zastosowania jako środek leczniczy do podania na skórę w zaburzeniach naskórka do stymulacji odbudowy naskórka |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
NZ253065A (en) | 1992-05-23 | 1996-10-28 | Smithkline Beecham Biolog | Combination vaccines comprising hepatitis b surface antigens and other antigens wherein aluminium phosphate adjuvant is used to adsorb the hepatitis antigen |
NL9201716A (nl) | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
ES2308962T3 (es) | 1995-06-07 | 2008-12-16 | Glaxosmithkline Biologicals S.A. | Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre. |
JP4162267B2 (ja) * | 1996-08-27 | 2008-10-08 | カイロン コーポレイション | Neisseria meningitidis血清型B複合糖質およびその使用法 |
ATE441432T1 (de) | 1997-03-10 | 2009-09-15 | Ottawa Hospital Res Inst | Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
AU7701098A (en) | 1997-05-28 | 1998-12-30 | Michael A. Apicella | Laft mutants of pathogenic gram-negative bacteria |
GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
WO1999010497A1 (en) | 1997-08-21 | 1999-03-04 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Novel mutants of gram negative mucosal bacteria and application thereof in vaccines |
US6645503B1 (en) | 1998-03-10 | 2003-11-11 | Wyeth Holdings Corporation | Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria |
NZ532665A (en) | 1998-05-01 | 2005-11-25 | Inst Genomic Research | Neisseria meningitidis antigens and compositions |
DK1535928T3 (da) | 1998-10-22 | 2008-10-20 | Univ Montana | Vaccinesammensætninger indeholdende Omp85-proteiner af Neisseria gonorrhoeae og Neisseria meningitidis |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
WO2000026384A1 (en) | 1998-11-03 | 2000-05-11 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Lps with reduced toxicity from genetically modified gram negative bacteria |
BRPI0010612B8 (pt) * | 1999-04-19 | 2021-05-25 | Smithkline Beecham Biologicals S A | vacinas |
GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
NZ571167A (en) | 1999-04-30 | 2010-05-28 | Novartis Vaccines & Diagnostic | Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
US6531131B1 (en) | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
WO2001034642A2 (en) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Control of neisserial membrane synthesis |
EP1234039A2 (en) | 1999-11-29 | 2002-08-28 | Chiron Spa | 85kDa NEISSERIAL ANTIGEN |
EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
US7947291B2 (en) | 2000-01-25 | 2011-05-24 | The University Of Queensland | Modified surface antigen |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
KR100799788B1 (ko) | 2000-06-08 | 2008-01-31 | 인터셀 아게 | 면역촉진성 올리고디옥시뉴클레오티드 |
JP5511117B2 (ja) | 2000-07-27 | 2014-06-04 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
PT2332581E (pt) | 2001-01-23 | 2015-10-16 | Sanofi Pasteur Inc | Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197 |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0202901D0 (en) | 2002-02-07 | 2002-03-27 | Glaxosmithkline Biolog Sa | Novel vaccine |
EP1476197B1 (en) | 2002-02-22 | 2009-01-07 | National Research Council Of Canada | Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue |
GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
CA2493124C (en) | 2002-08-02 | 2014-04-29 | Glaxosmithkline Biologicals S.A. | Vaccine |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
ATE492288T1 (de) | 2002-10-11 | 2011-01-15 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
JP4827726B2 (ja) * | 2003-01-30 | 2011-11-30 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 複数の髄膜炎菌血清群に対する注射可能ワクチン |
CN100355453C (zh) * | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | 改进的疫苗 |
AU2004224746B2 (en) | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
DK1742659T3 (da) | 2004-04-05 | 2013-06-03 | Zoetis P Llc | Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
JP4993750B2 (ja) | 2005-01-27 | 2012-08-08 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 髄膜炎菌に起因する疾患に対する広域防御のための、gna1870を基にした小胞ワクチン |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
CA2628206A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
JP5275982B2 (ja) | 2006-06-12 | 2013-08-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
BRPI0717219B8 (pt) | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
JP5415449B2 (ja) | 2007-12-24 | 2014-02-12 | ノバルティス アーゲー | 吸着されたインフルエンザワクチンのためのアッセイ |
ES2532946T3 (es) * | 2008-02-21 | 2015-04-06 | Novartis Ag | Polipéptidos PUfH meningocócicos |
-
2011
- 2011-03-18 EP EP11712679A patent/EP2547357A1/en not_active Withdrawn
- 2011-03-18 AU AU2011288203A patent/AU2011288203A1/en not_active Abandoned
- 2011-03-18 US US13/634,852 patent/US20130071422A1/en not_active Abandoned
- 2011-03-18 WO PCT/IB2011/051148 patent/WO2012020326A1/en active Application Filing
- 2011-03-18 CA CA2793510A patent/CA2793510A1/en not_active Abandoned
- 2011-03-18 JP JP2012557654A patent/JP2013522287A/ja active Pending
- 2011-03-18 CN CN2011800142952A patent/CN102802662A/zh active Pending
- 2011-03-18 BR BR112012022896A patent/BR112012022896A2/pt not_active IP Right Cessation
- 2011-03-18 MX MX2012010609A patent/MX2012010609A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2011288203A1 (en) | 2012-08-23 |
CA2793510A1 (en) | 2012-02-16 |
EP2547357A1 (en) | 2013-01-23 |
CN102802662A (zh) | 2012-11-28 |
JP2013522287A (ja) | 2013-06-13 |
MX2012010609A (es) | 2012-10-03 |
US20130071422A1 (en) | 2013-03-21 |
WO2012020326A1 (en) | 2012-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012022896A2 (pt) | vacinas adjuvantes para meningococos do sorogrupo b | |
ES2582284T3 (es) | Composición que comprende microbiota intestinal humana anaeróbicamente cultivada | |
CL2016001254A1 (es) | Mólecula unión cd3 capaz de unirse a cd3 humanos y no humanos (divisional de sol. 3329-13). | |
CL2012003299A1 (es) | Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma. | |
CL2012003625A1 (es) | Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas. | |
BR112016014488A2 (pt) | Meio para cultura celular | |
BR112013016711A2 (pt) | configuração de dispositivo dinâmico com o uso de predicados | |
CO6751288A2 (es) | Composición antigénica de micobacteria | |
BR112015011235A2 (pt) | sistema de travamento mecânico para painéis de piso | |
BR112015027830A2 (pt) | método e sistema de identificação de biomarcador | |
BRPI0812856A2 (pt) | Composições de vacina de emulsão que compreendem antígeno e adjuvante na fase aquosa. | |
BRPI0821003B8 (pt) | método para aumentar a imunorreatividade | |
BR112014004768A2 (pt) | método implementado por computador, sistema para pontuação de uma amostra obtida a partir de um indivíduo, meio de armazenamento legível por computador armazenando um código de programa executável por computador, método para pontuação e uma amostra obtida a partir de um indivíduo, kit para pontuação de uma amostra obtida a partir de um indivíduo, método para determinar o status de fumante de um indivíduo, sistema para determinar o status de fumante de um indivíduo e kit para uso na determinação de um status de fumante do indivíduo | |
BR112014004929A2 (pt) | conversão de unidades de alquilação de hf para processos de alquilação catalisada por líquido iônico | |
BR112012032339A2 (pt) | proporcionador de fluido de bomba dupla com posição de motor ajustável | |
BR112015015803A2 (pt) | interface de feed de capa social | |
BR112015009246A2 (pt) | métodos e sistemas para determinar o uso e o conteúdo de pymk com base em um modelo de valores | |
EP2762154A3 (en) | Vaccine composition for transdermal administration | |
BR112015025392A2 (pt) | composição de vacina e método de utilização | |
BR112014027867A2 (pt) | sistema de preparação de bebidas com meios de armazenamento e alimentação de doses individuais e processo de operação do referido sistema | |
BR112014002372A2 (pt) | recuperação de petróleo | |
AR090574A1 (es) | Metodo para preparar proteinas conjugadas por electrohilado | |
BR112015013012A2 (pt) | composição de sabão em barra e método para sua fabricação | |
CL2008000096A1 (es) | Combinacion farmaceutica que comprende dos compuestos uv-absorventes derivados de heptaazafenaleno; y su uso para tratar querotosis actinica, dermatitis, cronica, fotoenvejecimiento, urticaria solar, entre otras. | |
BR112014009166A2 (pt) | pá compacta para rotor de turbina francis e método para a configuração do rotor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |